Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nabpaclitaxel (nab-pac) as first-line ( 1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)